HTLV-II vaccine - Access
Latest Information Update: 27 Jun 2001
Price :
$50 *
At a glance
- Originator Access Pharmaceuticals
- Class Cancer vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HTLV-II infections
Most Recent Events
- 27 Jun 2001 No-Development-Reported for HTLV-II infections in USA (Unknown route)
- 04 Nov 1996 New profile
- 04 Nov 1996 Preclinical development for HTLV-II infections in USA (Unknown route)